Variable | Immunologic treatment failure | Total (%) | ||
---|---|---|---|---|
Yes (%) | No (%) | |||
Sex | Male | 32 (17.0) | 156 (83.0) | 188 (64.2) |
Female | 14 (13.6) | 89 (86.4) | 103 (35.2) | |
NR | 1 (50.0) | 1(50.0) | 2 (0.7) | |
Age (In years), at Month0 | Mean, SD | 34.6, 7.5 | 36.6, 8.5 | 36.7, 8.6 |
15–34 | 23 (18.1) | 104 (81.9) | 127 (43.5) | |
35–44 | 16 (13.3) | 104 (86.7) | 120 (41.1) | |
> = 45 | 6 (13.3) | 39 (86.7) | 45 (15.4) | |
Original First Line Regimen | D4T/3TC/NVP | 15 (13.0) | 100 (87.0) | 115 (39.2) |
D4T/3TC/EFV | 59 (78.7) | 16 (21.3) | 75 (25.6) | |
AZT/3TC/NVP | 32 (78.0) | 9 (22.0) | 41 (14.0) | |
AZT/3TC/EFV | 54 (91.5) | 5 (8.5) | 59 (20.1) | |
TDF/3TC/EFV | 2 (66.7) | 1 (33.3) | 3 (1.0) | |
Original Regimen substituted | Yes | 34 (16.8) | 168 (83.2) | 202 (68.9) |
No | 79 (87.8) | 11 (12.2) | 90 (30.7) | |
NR | 0 | 1 | 1 (0.3) | |
Switch to second line regimen | Yes | 2 (33.3) | 4 (66.7) | 6 (2.0) |
No | 44 (15.3) | 243 (84.7) | 287 (98.0) | |
Baseline CD4 count, cells/mm3 | Median, IQR | 122 (67–190) | 114 (63–176) | 115 (64–176) |
0–49 | 6 (12.8) | 41 (87.2) | 47 (16.2) | |
50–99 | 12 (16.0) | 63 (84.0) | 75 (25.9) | |
100–149 | 9 (14.3) | 54 (85.7) | 63 (21.7) | |
150–199 | 8 (12.9) | 54 (87.1) | 62 (21.4) | |
> = 200 | 10 (23.3) | 33 (76.7) | 43 (14.8) | |
Base line functional status | Work | 29 (15.9) | 153 (84.1) | 182 (62.1) |
Ambulatory | 9 (15.5) | 49 (84.5) | 58 (19.8) | |
Bedridden | 3 (12.0) | 22 (88.0) | 25 (8.5) | |
NR | 5 (17.9) | 23 (82.1) | 28 (9.6) | |
Body Mass Index. Kg/m2 | <18.5 | 12 (18.8) | 52 (81.2) | 64 (21.8) |
> = 18.5 | 15 (13.9) | 93 (86.1) | 108 (36.9) | |
NR | 19 (15.7) | 102 (84.3) | 121 (41.3) | |
Gap between testing and treatment initiation | Same month | 29 (17.0) | 142 (83.0) | 171 (59.0) |
1–24 months | 13 (13.4) | 84 (86.6) | 97 (33.4) | |
>24 months | 4 (18.2) | 18 (81.8) | 22 (7.6) | |
Adherence | Good | 35 (15.2) | 195 (84.8) | 230 (78.5) |
Fair/ poor | 10 (18.5) | 44 (81.5) | 54 (18.4) | |
NR | 1 (11.1) | 8 (88.9) | 9 (3.1) |